3, 7-diamino-10H-phenothiazine salts and their use
US-11344558-B2 · May 31, 2022 · US
Phenothiazine diaminium salts and their use
US12064439B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12064439-B2 |
| Application number | US-202117499498-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 12, 2021 |
| Priority date | Feb 11, 2011 |
| Publication date | Aug 20, 2024 |
| Grant date | Aug 20, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of general formula (I):and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A dosage unit comprising 20 to 300 mg of a compound of the following formula: or comprising 20 to 300 mg of a free base equivalent of said compound, and further comprising a pharmaceutically acceptable carrier, diluent, or excipient. 2. The dosage unit according to claim 1 , which is a tablet comprising 20 to 300 mg of the compound. 3. The dosage unit according to claim 1 , which is a capsule comprising 20 to 300 mg of the compound. 4. The dosage unit according to claim 1 , which comprises 30 to 200 mg of the compound. 5. The dosage unit according to claim 1 , which comprises about 30 mg of the compound. 6. The dosage unit according to claim 1 , in which less than 12% of said compound is converted to methylthionium: over 2 years when stored at 25° C. at a relative humidity of 60%. 7. The dosage unit according to claim 1 , which comprises about 60 mg of the compound. 8. The dosage unit according to claim 1 , which comprises about 100 mg of the compound. 9. The dosage unit according to claim 1 , which comprises about 150 mg of the compound. 10. The dosage unit according to claim 1 , which comprises about 200 mg of the compound. 11. The dosage unit according to claim 1 , which is a tablet comprising 20 to 300 mg of the free base equivalent of the compound. 12. The dosage unit according to claim 1 , which is a capsule comprising 20 to 300 mg of the free base equivalent of the compound. 13. The dosage unit according to claim 1 , which comprises 30 to 200 mg of the free base equivalent of the compound. 14. The dosage unit according to claim 1 , which comprises about 30 mg of the free base equivalent of the compound. 15. The dosage unit according to claim 1 , which comprises about 60 mg of the free base equivalent of the compound. 16. The dosage unit according to claim 1 , which comprises about 100 mg of the free base equivalent of the compound. 17. The dosage unit according to claim 1 , which comprises about 150 mg of the free base equivalent of the compound. 18. The dosage unit according to claim 1 , which comprises about 200 mg of the free base equivalent of the compound.
Assignees
Inventors
Classifications
Living organisms or biological materials · CPC title
Visible light · CPC title
of salts of sulfonic acids · CPC title
Naphthalene sulfonic acids · CPC title
of six-membered aromatic rings substituted by alkyl groups · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12064439B2 cover?
- Disclosed are compounds of general formula (I):and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
- Who is the assignee on this patent?
- Wista Lab Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D279/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).